“…45 In both cohorts, we observed previously that the nature of the mutation, disruptive or missense, could explain a certain heterogeneity of residual degranulation, as described for FHL3 patients. 46 In contrast, resting NK-cell degranulation was above 5% in 29 of 30 patients (97%) with FHL2 or with 1 of the 2 XLP variants and in 58 of 59 patients (98%) with secondary HLH. Therefore, as suggested previously in smaller studies, 29,30,37,42 the assay clearly discriminated between patients with genetic disorders predisposing to HLH that are associated with impaired degranulation and those that are not.…”